What is the Origin of SURPASS Clinical Trials?

The trial name, SURPASS, was chosen by the sponsor, Eli Lilly and Company, to convey the drug's potential to "surpass" the performance of existing single-agonist therapies in both blood sugar control and weight management. This program was initiated in the late 2010s, building upon the clinical success of earlier incretin mimetics, aiming to demonstrate a new standard of care by targeting two complementary metabolic pathways simultaneously.

What is the Mechanism of SURPASS Clinical Trials?

The trials function by randomizing participants with type 2 diabetes to receive varying doses of the dual GIP/GLP-1 agonist or comparator drugs, meticulously measuring endpoints like the change in HbA1c and body weight over a period of many months. The therapeutic mechanism involves the dual agonism stimulating glucose-dependent insulin secretion, suppressing glucagon release, and enhancing satiety. The SURPASS data provided the evidence base demonstrating that this synergistic hormonal action significantly improves metabolic health markers, confirming the drug's profound effect on glucose and energy homeostasis.

SURPASS Clinical Trials ∞ Area

SURPASS Clinical Trials

Meaning

The SURPASS Clinical Trials are a pivotal, global phase 3 research program that established the efficacy and safety profile of the dual GIP/GLP-1 receptor agonist, tirzepatide, for the treatment of adults with type 2 diabetes. This extensive trial series focused on assessing the drug’s ability to achieve superior glycemic control and significant body weight reduction compared to existing diabetes medications and placebo. The results of the SURPASS program were foundational to the drug’s initial regulatory approval for diabetes management.

A botanical specimen transitions from delicate grey fibers to a structured green spike. This symbolizes the patient journey from hormonal imbalance within the endocrine system to hormone optimization through precise HRT protocols, fostering cellular repair and reclaimed vitality for metabolic health.

What Are the Long-Term Safety Profiles of Dual Incretin Agonists?

Dual incretin agonists have a well-characterized long-term safety profile consistent with GLP-1 RAs, primarily involving manageable, transient GI effects.

∞ Receptor Agonists
∞ Clinical Trial Data
∞ Side Effects

HRTioAugust 1, 2025

SURPASS Clinical Trials

Meaning

Origin

Mechanism

What Are the Long-Term Safety Profiles of Dual Incretin Agonists?

Provided by the clinical team
at 4Ever Young Miami Dadeland

-15% ∞ HRTIO15

Your protocol begins with a conversation.

Visit

Schedule Appointment

About

Med & Wellness

4Ever Young Miami Dadeland

Communication

+1 786-529-6686

Email Us

Opening Hours